Active, not recruitingPhase 1NCT06925919
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011
Studying Coccidioidomycosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IDBiologics, Inc.
- Intervention
- IDB-011 dose level 1(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Altasciences Clinical Los Angeles, Cypress, California, United States
Collaborators
Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06925919 on ClinicalTrials.govOther trials for Coccidioidomycosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06799234Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)University of Oxford
- ACTIVE NOT RECRUITINGNANCT06913803To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum FemalesSuperior University
- RECRUITINGPHASE2NCT03609398Phase 2 Safety and Immunogenicity Study of Rift Valley Fever VaccineU.S. Army Medical Research and Development Command
- RECRUITINGNCT02190266Pathogenesis and Genetics of Disseminated or Refractory CoccidioidomycosisNational Institute of Allergy and Infectious Diseases (NIAID)